CK Life Sciences International, (Holdings) Inc. announced positive results from its Phase III clinical trial of a new drug. The trial, designed to evaluate the drug’s efficacy and safety, met its primary endpoints. The data indicates that the new drug offers a statistically significant improvement over the current standard treatment. Further details regarding the trial’s findings will be presented at an upcoming medical conference.